A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 28 Feb 2018
At a glance
- Drugs Selonsertib (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Registrational; Therapeutic Use
- Acronyms STELLAR 4
- Sponsors Gilead Sciences
- 23 Feb 2018 Planned End Date changed from 1 Oct 2023 to 1 Nov 2022.
- 23 Feb 2018 Planned primary completion date changed from 1 Jan 2020 to 1 Jan 2019.
- 23 Feb 2018 Status changed from recruiting to active, no longer recruiting.